Market Closed - Nasdaq Stockholm 11:29:37 2024-05-20 am EDT 5-day change 1st Jan Change
0.0499 SEK -10.25% Intraday chart for S2Medical AB +6.62% -16.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
S2Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
S2Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
S2Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
S2Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
S2medical AB Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkey Market CI
S2Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
S2Medical Raises SEK22 Million Via Rights Issue MT
Medical Devices Group S2Medical Gets New Loan; Shares Down 13% MT
S2Medical AB Secures New Loan Agreement CI
S2Medical to Raise SEK22 Million in Rights Issue MT
S2medical AB Signs Manufacturing Agreement with Distributor in Saudi Arabia CI
S2Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
S2Medical AB Signs Distribution Agreement for Iranian Market with Avije Teb Parsin CI
S2Medical AB Wins Procurement for Wound Healing Items in the United Arab Emirates Worth Approximately SEK 3.4 Million CI
S2Medical AB Wins Procurement for Wound Healing Equipment in Region Halland CI
S2Medical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
S2Medical AB Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria CI
S2Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
S2medical AB Announces Postponing of Publication of the Quarterly Report for the Period July - September CI
S2Medical Set to Win Europe Patent for Antimicrobial Peptides Technology MT
EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology CI
Region Östergötland Signs Direct Purchase Agreement for its within S2Mededical's Wound Healing Portfolio CI
S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia CI
S2Medical Enters Exclusive Deal with Molecular Farma for Portugal Distribution MT
S2medical Ab: S2medical AB Signs Exclusive Distribution Agreement for Portugal CI
Chart S2Medical AB
More charts
S2Medical AB (publ) is a Sweden-based medical technology company. The Company focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The Company's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The Company is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
More about the company
  1. Stock Market
  2. Equities
  3. S2M Stock
  4. News S2Medical AB
  5. S2Medical to Raise SEK22 Million in Rights Issue
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW